Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ERIC 2018 | Microenvironmental interactions and signaling pathways in CLL

Silvia Deaglio • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

Silvia Deaglio, MD, PhD, of the University of Turin, Turin, Italy, discusses our current knowledge of the microenvironmental interactions and signaling pathways in chronic lymphocytic leukemia (CLL). This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Silvia Deaglio

Future advancements in the treatment of CLL 1:33
Future advancements in the treatment of CLL
Silvia Deaglio • 31 Aug 2021
Utilizing the NOTCH1 pathway in the treatment of CLL 1:37
Utilizing the NOTCH1 pathway in the treatment of CLL
Silvia Deaglio • 31 Aug 2021
The molecular and microenvironmental basis of immunodysfunction in CLL 1:44
The molecular and microenvironmental basis of immunodysfunction in CLL
Silvia Deaglio • 31 Aug 2021
Utilizing the NOTCH1 pathway in CLL treatment 2:28
Utilizing the NOTCH1 pathway in CLL treatment
Silvia Deaglio • 21 Sep 2019

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals